Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Peanut Oral Immunotherapy
NCT07015996Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2026
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tezepelumab in peanut allergy, sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT07015996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015996.